). Using the Andersen-Gill proportional hazards regression model for the analysis of relapse-free survival, we found that PCR-positive findings in samples from BM and/or PB at any given time-point after transplantation were associated with an increased estimated hazard ratio of 4.5 in comparison with a PCR-negative finding (P = 0.013). On the other hand, patients included while they were in first remission had a smaller estimated hazard ratio of 0.3 when compared with patients with a history of previous treatment failure (P = 0.048). For the latter group of patients, this translates into a significantly smaller probability of relapse-free survival in comparison to patients who were in first remission at the time of PBSC-mobilization (P = 0.012). In conclusion, the remission status of the patients before autografting and the PCR status as assessed on the occasion of follow-up examinations are significant prognostic parameters for relapse-free survival in patients with follicular lymphoma undergoing high-dose therapy with PBSC autografting.
Introduction
There is an increasing number of reports on the use of peripheral blood stem cells (PBSC) for supporting high-dose therapy in patients with malignant lymphoma. [1] [2] [3] [4] In contrast to allogeneic stem cell transplantation, autografting always carries the risk of re-infusing tumor cells which may contribute to recurrence of disease. [5] [6] [7] [8] [9] This was concluded from studies of Brenner et al 10 with chronic myeloid leukemia. On the other hand, it has been argued that relapse may arise from resistant cells in vivo rather than from those transplanted, since relapse after autologous marrow or PBSC transplantation often involves sites of previous disease. 12 The question of minimal residual disease (MRD) can be addressed using molecular biological methods as some lymphoid malignancies have chromosomal aberrations suitable for detection by polymerase chain reaction (PCR). [13] [14] [15] For instance, between 63 and 82% of patients with follicular non-Hodgkin's lymphoma (NHL) have malignant cells with a translocation involving the B cell lymphoma-2 (bcl-2) gene on chromosome 18q21 and the joining regions of the immunoglobulin heavy chain gene on chromosome 14q32. 16, 17 Therefore, PCR permits us to look for translocation-positive cells at a sensitivity level of approximately 1 in 10 5 .
In the study presented here, 47 patients with low-grade NHL carrying the t(14;18) translocation received high-dose therapy with PBSC support. Using a nested PCR, samples from bone marrow (BM) and peripheral blood (PB), as well as from leukapheresis (LP) products were examined for the presence of t(14;18)-positive cells. We were particularly interested in samples obtained following myeloablative therapy and PBSC transplantation in order to evaluate the prognostic significance of the PCR results observed.
Patients and methods

Patients
Between May 1992 and December 1997, 47 patients (26 males/21 females) with centrocytic-centroblastic (cc-cb) NHL according to the Kiel classification were enrolled on to the study. Following the REAL classification, cc-cb NHL closely corresponds to follicular NHL. The patients had a median age of 45 years (range, 26-56 years). Twenty-five patients were included into the protocol after having achieved partial remission (PR) (16 patients) or complete remission (CR) (nine patients) following first-line therapy. On the other hand, 10 patients had a history of relapse and were referred to our center after having responded to second-line therapy. Four patients had achieved second CR, while six patients were in second PR. There were also 11 patients in relapse who received high-dose cytarabine and mitoxantrone (HAM) with G-CSF-support as salvage treatment. One patient had progressive disease at the time of entry into the study.
The time elapsed between initial diagnosis and start of PBSC mobilization varied between 4 and 115 months (median, 10 months). Pretreatment consisted of a median of six cycles (range, 0-15) of cytotoxic chemotherapy. Three patients with a history of treatment failure had previously received radiotherapy including total-nodal, mantle-field and involved-field irradiation. According to the histopathological examination, 20 patients had evidence of bone marrow involvement before the mobilization chemotherapy began. The patients' characteristics are summarized in Table 1 .
Independent of the disease status at the time of entry into the study, the patients received high-dose cytarabine (2 g/m 2 q 12 h on days 1 and 2) and mitoxantrone (10 mg/m 2 /day on days 2 and 3). Filgrastim (R-metHuG-CSF, 300 g/day, subcutaneously; Amgen, Thousand Oaks, CA, USA) was commenced 24 h after completion of cytotoxic chemotherapy to enhance the rebound of circulating hematopoietic progenitor cells during marrow recovery.
The collection of PBSC was performed using a Fenwal CS 3000 (Baxter, Mü nchen, Germany) or a Cobe Spectra (COBE, Lakewood, CO, USA). Harvesting began when a distinct CD34
+ cell population was found by immunofluorescence analysis. Between 10 l and 20 l blood per apheresis were processed at flow rates between 70 and 150 ml/min.
Pretransplant conditioning therapy consisted of total body irradiation (TBI, 14.4 Gy, hyperfractionated over 4 days) and cyclophosphamide (200 mg/kg, over 4 days) in 44 patients, while three patients with previous radiotherapy received carmustine 300 mg/m 2 , etoposide 1200 mg/m 2 , cytarabine 800 mg/m 2 , and melphalan 140 mg/m 2 (BEAM). The study includes 38 patients who were part of a clinical trial evaluating the efficacy of a sequential high-dose therapy with peripheral blood stem cell support. 18 The study was performed under the ethical guidelines of the Joint Committee of Clinical Investigation of the University of Heidelberg. Informed consent was obtained from each patient. The cut-off date of this report is 31 December 1997.
Samples from bone marrow and peripheral blood
Samples from BM and/or PB were obtained before the start of cytotoxic chemotherapy. In 44 patients samples from both 
Polymerase chain reaction
Mononuclear cells from samples of BM, PB and LP products were obtained following separation by Ficoll (Biochrom, Berlin, Germany). Genomic DNA was isolated by cell lysis with nonionic detergents and proteinase K (Boehringer, Mannheim, Germany). DNA was precipitated with isopropanol and the pelleted DNA was redissolved in TE 10/1 (10 mm Tris-HCl, 1 mm EDTA, pH 8.0). Isolated DNA could be amplified using an internal primer pair of the bcl-2 gene itself covering a 200 bp fragment (Dianova, Hamburg, Germany). Using a nested-primer assay, recombination-specific PCR analyses were performed at the major breakpoint regions (MBR) or minor cluster region (mcr) of the bcl-2/immunoglobulin (IgH) locus with an initial amount of 2 g of DNA. Compared with the method described previously, some minor modifications were made:
19 re-amplification of a 2 l aliquot of the first PCR round was performed using oligonucleotides elongated at their 5Ј end with so-called cloning tails for the MBR and mcr primer with 5Ј CTGGTTCTGCCCA 3Ј and for the JH primer with 5Ј CTCGCTCGCCCA 3Ј permitting an efficient cloning of the obtained products in the pdirect vector (Clontech, Palo Alto, CA, USA) for sequencing of the individual breakpoint regions. Primers comprising the minor cluster region were those described by Gribben et al. 20 The PCR products were excised for cloning from low melting point agarose gels, and the DNA was recovered and purified with the SpinBind DNA Recovery System for agarose gels (FMC, Rockland, ME, USA). Cloning and transformation were performed with the p-direct cloning system (Clontech). Double-stranded DNA templates were sequenced by the method of Sanger et al 21 in order to determine the individual breakpoint regions of the patients for exclusion of crosscontaminations of samples.
In order to demonstrate the sensitivity of the PCR assay, 2 g of DNA (equivalent to 3.3 × 10 5 cells) of the t(14;18) positive cell line K422 was diluted over a 6-log rank from 200 ng to 20 pg with placental DNA (Clontech), maintaining a DNA amount of 2 g per reaction assay. At the 20 pg level of K422 DNA, the PCR was reproducibly positive after the second amplification round and was therefore included as positive control in each experiment. PCR assays without added DNA served as negative controls. Each sample was analyzed on at least two occasions.
Statistical analysis
The clinical and laboratory data were retrieved from the patient data base. The PCR status of a patient post-transplantation was rated as negative, if samples from both sources, BM and PB, were free of t(14;18)-positive cells. The PCR status was considered positive, if BM and/or PB samples contained PCR-positive cells. The Andersen-Gill proportional hazards regression model was used for the analysis of survival time data with time-dependent covariates. [22] [23] [24] For instance, a patient with PCR results performed in the autograft as well as 4 and 8 months after transplantation with a follow-up time of 11 months would be rated in three time intervals: 0-4, 4-8 and 8-11 months. This statistical procedure implies that the time-dependent covariate follows a stepwise function with jumps at the measurement points. Since changes of the PCR status in the patient are more likely to happen during the time interval between the measurements, the midpoints of the measurements were used for the evaluation of the time-dependent covariate (Figure 1 ). The estimate of the survival curves was computed using the Kaplan-Meier method. Two-sided 95% confidence intervals for the survival curves were computed on the cumulative-hazard scale. The log-rank test was used to evaluate the statistical significance of differences in the relapse-free survival between patient groups. A difference was always considered as statistically significant, if the P value was smaller than or equal to 5% (P р 0.05). The statistical computations were performed using S-Plus, Version 3.4 (MathSoft Inc, 1996) on a Sun SPARCstation.
Results
Cytotoxic chemotherapy with high-dose cytarabine and mitoxantrone for PBSC mobilization
Since May 1992, 47 patients with a t(14;18)-positive follicular NHL were eligible for the assessment of minimal disease and residual tumor cells in samples from BM, PB and LP products. Since material from lymph nodes or bone marrow biopsies obtained at the time of diagnosis were not available, the first molecular assessment was performed before PBSC mobilization at the time of entry into the study. Of the 47 patients examined, 43 presented with PCR-positive cells in BM and/or PB. Four patients with PCR-negative BM and PB samples were included later, as t(14;18)-positive cells were found in their LP products. The t(14;18) translocation involved the major breakpoint region in 45 patients and the minor cluster region in two patients.
During the time of G-CSF-enhanced leukocyte recovery, PBSC were harvested resulting in a collection efficiency of 3.85 × 10 6 CD34 + cells/kg/leukapheresis (range, 0.13-41.0 × 10 6 ). For the assessment of cells bearing the t(14;18) translocation, a total of 129 LP products were examined. PCR-positive cells were found in 96 LP products (74%) of 38 patients. This includes four patients without detectable t(14;18)-positive cells before mobilization and four patients presenting with PCR-positive, as well as PCR-negative harvests. They could receive a PCR-negative autograft, since their PCR-negative LP products contained a number of CD34 + cells greater than 2.5 × 10 6 CD34 + cells/kg. There were also nine patients with PCR-positive BM and/or PB samples before PBSC mobilization who became PCR-negative in their LP harvests. Thus, 13 patients (28%) received a PCR-negative autograft following high-dose conditioning therapy, while 34 patients (72%) were autografted with PCR-positive LP products (Figure 1 ).
Figure 2
Kaplan-Meier plot of relapse-free survival for 47 patients who had undergone high-dose therapy with PBSCT, including the 95% confidence limits. Curves are marked at each censoring time which is not also a relapse time. Dotted lines show a two-sided 95% confidence interval on the survival curve.
PBSC-supported high-dose therapy and detection of residual disease post-transplantation
A median number of 6.1 CD34
+ cells/kg (range, 2.1-41.0 × 10 6 ) were autografted resulting in a recovery of neutrophils to counts of 0.5 × 10 9 /l after a median time of 13 days (range, 10-34) and in a recovery of platelets to counts of 20.0 × 10 9 /l after a median time of 11 days (range, 3-51). There were no transplantation-related toxic deaths permitting us to evaluate the PCR status and relapse-free survival in all patients.
A total of 171 BM and 195 PB samples were obtained posttransplantation after a median time of 20 months (range, 6-50) on the occasion of regular follow-up visits. After a median follow-up time of 20 months (range, 6-50), 33 patients were in remission, whereas 14 patients had relapsed following a median time of 14.5 months (range, 10-42). As a result, the probability for relapse-free survival at 50 months was 40% (Figure 2 ). For the analysis of survival data with time-dependent covariates, the Andersen-Gill proportional hazards regression model was used to extend the Cox model for censored data for time-dependent covariates.
The following prognostic factors were considered: the age of the patient at the time of PBSCT (Ͻ 45 years vs Ͼ 45 years), the stage of the disease (IV vs II and III), the remission status at the time of PBSC mobilization therapy (first remission vs second remission), the PCR status of the autograft (PCR-positive vs PCR-negative) and the time-dependent PCR status observed on the occasion of follow-up examinations (PCRpositive vs PCR-negative). Statistically significant differences were found with respect to the remission status at the time of PBSC mobilization and autografting (P = 0.048), respectively, and for the PCR status post-transplantation (P = 0.013). Patients in first remission had a significantly lower estimated hazard ratio for relapse of 0.3 (with 95% confidence limit: 0.09, 0.99) compared with patients in second remission. Looking at the respective Kaplan-Meier estimates, we found that patients included while they were in first remission had Probability of relapse-free survival (RFS) in patients in first remission (solid line) vs patients with a history of previous treatment failure (dotted line) with a median follow-up of 20 months (range, 6-50 months). The probability of RFS was greater in patients in first remission in comparison to patients with a history of previous treatment failure (P = 0.012).
a significantly greater probability of relapse-free survival than patients entered on to the protocol with a history of previous treatment failure (Figure 3) .
On the other hand, a PCR-positive result obtained during the follow-up period indicated a significantly greater estimated hazard ratio for relapse of 4.5 (95% confidence limit: 1.4, 15) compared with a PCR-negative finding (Table 2) . It was interesting to note that the five relapses which we observed after a follow-up time of more than 20 months occurred in a group of 10 patients who presented with PCRpositive findings on the occasion of their last follow-up examination. In contrast, in 13 patients with PCR-negative results observed during a similar follow-up period there was no disease recurrence observed.
Discussion
The study was carried out to examine the prognostic value of PCR findings in patients with t(14;18)-positive follicular NHL. The patients underwent a sequential treatment consisting of G-CSF-supported high-dose cytarabine and mitoxantrone followed by myeloablative conditioning therapy with PBSC autografting. Samples of BM and PB were first obtained before PBSC mobilization. Following G-CSF-supported cytotoxic therapy, PCR-positive cells from PB were found in 74% of the LP products. This proportion is greater than that reported by Hardingham et al 25 as well as Corradini et al. 26 They found that between 50 and 58% of blood-derived harvests from patients with t(14;18)-positive NHL contained PCR-positive cells, respectively. Corradini et al suggested that the more intensive pretransplant therapy that their patients had could account for the differences observed. The comparison of our data with the results of Hardingham et al is hampered, since they used only a single round of PCR instead of two as we have done. Still, nine patients in our group with PCR-positive BM and/or PB samples before PBSC mobilization had PCRnegative LP products which reflects the efficacy of the cytotoxic chemotherapy in lowering the tumor load in vivo. Eight of these patients were in first remission at the time of mobilization, suggesting that the likelihood of PCR conversion might be related to the stage of the disease. The prognostic significance of the remission status at the time of PBSC mobilization for relapse-free survival after transplantation could be demonstrated, as a decreased estimated hazard ratio for relapse was found for patients included while they were in first remission. In comparison to patients with a history of previous treatment failure, they had a significantly greater probability of relapse-free survival, when a KaplanMeier estimate was performed (P = 0.012).
These data confirm our previous findings in a group of 48 patients with follicular NHL who had received high-dose therapy with PBSC transplantation. 18 In those patients including 21% of cases with t(14;18)-negative NHL, the estimated probability of disease-free survival at 2 years tended to be greater in patients autografted in first remission compared with patients transplanted in second or higher remission.
Following sequential cytotoxic chemotherapy including PBSC-supported myeloablative therapy, we also observed a relationship between the patients' PCR results obtained on the occasion of follow-up examinations and the risk of developing a relapse. A positive PCR finding at any given time-point after transplantation indicated a 4.5-fold greater estimated hazard ratio in comparison to a negative PCR result. We also found that in a group of 23 patients with a follow-up time post-transplantation between 20 and 50 months, five relapses occurred in a group of 10 patients who presented with a PCR-positive result on the occasion of their last follow-up visit. In contrast, none of the 13 patients with PCR-negative findings relapsed.
Our results are in line with the report of Freedman et al 27 who demonstrated a strong relationship between the probability of disease-free survival and the PCR results obtained from BM specimens collected after transplantation. In particular, they found that continued PCR negativity in follow-up samples is highly predictive for continuous complete remission. Our findings are also consistent with the data of Hardingham et al 28 demonstrating that persistence of PCRpositive cells in patients with NHL after autologous PBSCT was associated with an increased risk of relapse. These data could be of relevance, as adjuvant treatment modalities may be available for eradication of minimal disease. For instance, the use of a humanized monoclonal antibody directed against the CD20 antigen (IDEC-C2B8) has shown to be effective in poor risk patients with an intention to treat response of 46%. 29 The monoclonal antibody might be even more efficacious at a time when the in vivo tumor burden has been substantially reduced following myeloablative high-dose therapy recognizable by sequential PCR analyses. In the same line, administration of ␣-interferon might be considered for patients presenting with persistence of PCR-positive cells in BM and PB samples post-transplantation. 30 From the data presented here, one cannot conclude whether PCR-positive cells in the autografts contributed to recurrence of disease or whether they merely indicated an increased tumor burden in vivo associated with a greater likelihood of treatment failure. The data of Johnson et al 31 support the notion that relapse more likely results from the failure of myeloablative treatment than from re-infusion of malignant cells. Still, considering the availability of an efficient adjuvant treatment post-transplantation, the depletion of contaminating tumor cells from the autograft may become more relevant. In that respect, our efforts are geared towards newer purging techniques combining a CD34
+ cell selection with further depletion using monoclonal antibodies directed against B cellassociated antigens.
In summary, the PCR results obtained from bone marrow or blood-derived samples in patients with t(14;18)-positive NHL on the occasion of follow-up examinations post-transplantation and the remission status of the patient at the time of PBSC mobilization were found to be independent prognostic factors for the probability of relapse-free survival following autotransplantation.
